Bardzo tanie apteki z dostawą w całej Polsce kupic viagra i ogromny wybór pigułek.

Vpgcorp.com2

TABLE OF CONTENTS
 To request sample pages please contact us at [email protected]  8 EXECUTIVE SUMMARY  9 METHODOLOGY AND MARKET DEFINITION  9 Market definition for inflammatory bowel disease  12 Patient-based forecast methodology  19 Physician sample breakdown  20 Contributing experts  20 Bibliography  22 MARKET FORECAST ANALYSIS  22 Biosimilars to erode biologics' market share and create a highly competitive IBD market  23 Dynamics in the IBD forecast by line of therapy  24 Ulcerative colitis market is forecast to overtake the Crohn’s disease market after 2016  26 High proportion of patients on 5-ASAs and corticosteroids but anti-TNF drive sales  33 US  34 Japan  35 Five major EU markets  37 AJM300  37 Forecast assumptions  37 Bibliography  38 APRISO (MESALAZINE)  38 Forecast assumptions  39 Apriso forecast 2012–21  41 Bibliography  42 ASACOL/ASACOL HD (MESALAZINE)  42 Forecast assumptions  44 Asacol/Asacol HD forecast 2012–21  46 Bibliography  47 BUDENOFALK (BUDESONIDE)  47 Forecast assumptions  49 Budenofalk forecast 2012–21  52 Bibliography  54 CIMZIA (CERTOLIZUMAB)  54 Forecast assumptions  56 Cimzia forecast 2012–21  57 Bibliography  58 ENTOCORT (BUDESONIDE)  58 Forecast assumptions  59 Entocort forecast 2012–21  61 Bibliography  62 HUMIRA (ADALIMUMAB)  62 Forecast assumptions  66 Humira forecast 2012–21  68 Bibliography  70 LIALDA (MESALAZINE MMX)  71 Lialda forecast 2012–21  74 LMW HEPARIN MMX (PARNAPARIN)  74 Forecast assumptions  74 Bibliography  75 REMICADE (INFLIXIMAB)  75 Forecast assumptions  79 Remicade forecast 2012–21  81 Bibliography  82 SIMPONI (GOLIMUMAB)  82 Forecast assumptions  83 Simponi forecast 2012–21  85 Bibliography  86 STELARA (USTEKINUMAB)  87 Stelara forecast 2012–21  89 Bibliography  91 TOFACITINIB (CP-690,550)  91 Forecast assumptions  92 Tofacitinib forecast 2012–21  94 Bibliography  95 TYSABRI (NATALIZUMAB)  95 Forecast assumptions  96 Tysabri forecast 2012–21  99 UCERIS (BUDESONIDE)  99 Forecast assumptions  100 Uceris forecast 2012–21  101 Bibliography  102 VEDOLIZUMAB (MLN0002)  102 Forecast assumptions  103 Vedolizumab forecast 2012–21  105 Bibliography  107 VERCIRNON (GSK1605786, FORMERLY TRAFICET-EN)  107 Forecast assumptions  107 Vercirnon forecast 2012–21  110 APPENDIX  110 Primary research questions  12 Figure 1: Patient-based forecast methodology for inflammatory bowel disease,  22 Figure 2: Inflammatory bowel disease sales of marketed and pipeline biologics across the  23 Figure 3: Inflammatory bowel disease sales ($m) and patient numbers (000s) across the seven major markets, by line of therapy, 2012–21  24 Figure 4: Drivers for increasing ulcerative colitis market relative to Crohn’s disease across  26 Figure 5: Inflammatory bowel disease sales ($m) and patient numbers (000s) across the seven major markets, by class, 2012–21  27 Figure 6: Inflammatory bowel disease market sales across the seven major markets ($m),  28 Figure 7: Inflammatory bowel disease patient numbers across the seven major markets  33 Figure 8: Inflammatory bowel disease-specific sales in the US, by class ($m), 2012–21  35 Figure 9: Inflammatory bowel disease-specific sales in Japan, by class ($m), 2012–21  36 Figure 10: Inflammatory bowel disease sales in the five major EU markets, by class ($m),  39 Figure 11: Apriso (mesalazine; Ajinomoto/Dr Falk Pharma/Salix Pharmaceuticals) sales forecasts in inflammatory bowel disease across the seven major markets ($m), 2012–21  44 Figure 12: Asacol (mesalazine; Warner Chilcott/Zeria/Kyowa Hakko Kirin) sales forecasts in inflammatory bowel disease across the seven major markets ($m), 2012–21  44 Figure 13: Asacol HD (mesalazine; Warner Chilcott/Zeria/Kyowa Hakko Kirin) sales forecasts in inflammatory bowel disease in the US and the UK ($m), 2012–21  49 Figure 14: Budenofalk foam (budesonide; Dr Falk Pharma/Salix Pharmaceuticals) sales forecasts in inflammatory bowel disease in the seven major markets ($m), 2012–21  50 Figure 15: Budenofalk capsule (budesonide; Dr Falk Pharma/Salix Pharmaceuticals) sales forecasts in inflammatory bowel disease in the EU ($m), 2012–21  56 Figure 16: Cimzia (certolizumab; UCB) sales forecasts in Crohn’s disease across the US and five major EU markets, ($m), 2012–21  59 Figure 17: Entocort EC (budesonide; Prometheus/AstraZeneca) sales forecasts in inflammatory bowel disease in the seven major markets ($m), 2012–21  67 Figure 18: Humira (adalimumab; Abbott/Eisai) sales forecasts in inflammatory bowel disease across the seven major markets, ($m), 2012–21  71 Figure 19: Lialda (mesalazine MMX; Cosmo/Giuliani/Mochida/Shire) sales forecasts in inflammatory bowel disease across the seven major markets ($m), 2012–21  79 Figure 20: Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales forecasts in inflammatory bowel disease across the seven major markets, ($m), 2012–21  83 Figure 21: Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales forecasts in ulcerative colitis, across the seven major markets, ($m), 2012–21  87 Figure 22: Stelara (ustekinumab; Janssen Biotech/Janssen-Cilag/Johnson & Johnson) sales forecasts in Crohn’s disease, across the US and five major EU markets ($m), 2012–21  92 Figure 23: Tofacitinib (formerly tasocitinib, CP-690,550; Pfizer) sales forecasts in ulcerative colitis across the seven major markets, ($m), 2012–21  96 Figure 24: Tysabri (natalizumab; Biogen Idec/Elan) sales forecasts in Crohn’s disease in  100 Figure 25: Uceris (budesonide MMX; Cosmo/Ferring/Santarus) sales forecasts in ulcerative colitis, across the US and five EU major markets ($m), 2012–21  103 Figure 26: Vedolizumab (MLN0002; Takeda/Millennium Pharmaceuticals) sales forecasts in inflammatory bowel disease, across the US and five major EU markets ($m), 2012–21  108 Figure 27: Vercirnon (GSK1605786, formerly Traficet-EN; ChemoCentryx/GlaxoSmithKline) sales forecasts in Crohn’s disease across the seven major markets ($m), 2012–21  9 Table 1: Summary of drug classes and molecules in Datamonitor’s inflammatory bowel disease patient-based forecast, September 2012  13 Table 2: Price sources and calculations, by country, September 2012  15 Table 3: Exchange rates used for calculating prices, September 2012  16 Table 4: Patent expiry dates for key marketed brands in inflammatory bowel disease across the seven major markets, September 2012  18 Table 5: Estimated launch dates for key late-stage pipeline products and marketed brands in inflammatory bowel disease in the seven major markets, 2012–21  20 Table 6: Physician sample breakdown, 2012  29 Table 7: Inflammatory bowel disease market sales across the seven major markets ($m),  38 Table 8: Datamonitor’s price assumptions for Apriso  40 Table 9: Apriso (mesalazine; Ajinomoto/Dr Falk Pharma/Salix Pharmaceuticals) sales forecasts in inflammatory bowel disease in the across the seven major markets ($m), 2012–21  42 Table 10: Datamonitor’s price assumptions for Asacol and Asacol HD  45 Table 11: Asacol/Asacol HD (mesalazine; Warner Chilcott/Zeria/Kyowa Hakko Kirin) sales forecasts in inflammatory bowel disease across the seven major markets ($m), 2012–21  47 Table 12: Datamonitor’s price assumptions for Budenofalk (rectal foam and oral capsule)  51 Table 13: Budenofalk foam/Budenofalk oral capsule (budesonide; Dr Falk Pharma/Salix Pharmaceuticals) sales forecasts in inflammatory bowel disease in the US, ($m), 2012–21  55 Table 14: Datamonitor’s price assumptions for Cimzia  56 Table 15: Cimzia (certolizumab; UCB) sales forecasts in Crohn’s disease across the  58 Table 16: Datamonitor’s price assumptions for Entocort  60 Table 17: Entocort EC (budesonide; Prometheus/AstraZeneca) sales forecasts in inflammatory bowel disease in the US ($m), 2012–21  62 Table 18: Adalimumab biosimilars in clinical development  66 Table 19: Datamonitor’s price assumptions for Humira  67 Table 20: Humira (adalimumab; Abbott/Eisai) sales forecasts in inflammatory bowel disease across the seven major markets, ($m), 2012–21  70 Table 21: Datamonitor’s price assumptions for Lialda  72 Table 22: Lialda (mesalazine MMX; Cosmo/Giuliani/Mochida/Shire) sales forecasts in inflammatory bowel disease across the seven major markets ($m), 2012–21  76 Table 23: Infliximab biosimilars in clinical development  78 Table 24: Datamonitor’s price assumptions for Remicade  80 Table 25: Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck &  Tanabe) sales forecasts in inflammatory bowel disease across the seven major markets,  84 Table 26: Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales forecasts in ulcerative colitis, across the seven major markets ($m), 2012–21  88 Table 27: Stelara (ustekinumab; Janssen Biotech/Janssen-Cilag/Johnson & Johnson) sales forecasts in Crohn’s disease, across the US and five major EU markets ($m), 2012–21  93 Table 28: Tofacitinib (formerly tasocitinib, CP-690,550; Pfizer) sales forecasts in ulcerative colitis across the seven major markets ($m), 2012–21  96 Table 29: Datamonitor’s price assumptions for Tysabri  97 Table 30: Tysabri (natalizumab; Biogen Idec/Elan) sales forecasts in Crohn’s disease in  100 Table 31: Uceris (budesonide MMX; Cosmo/Ferring/Santarus) sales forecasts in ulcerative colitis, across the seven major markets, ($m), 2012–21  104 Table 32: Vedolizumab (MLN0002; Takeda/Millennium Pharmaceuticals) sales forecasts in inflammatory bowel disease, across the seven major markets ($m), 2012–21  108 Table 33: Vercirnon (GSK1605786, formerly Traficet-EN; ChemoCentryx/GlaxoSmithKline) sales forecasts in Crohn’s disease across the seven major markets, ($m), 2012–21

Source: http://www.vpgcorp.com/webfiles/TOCThe%20Inflammatory%20Bowel%20Disease%20Market%20Outlook%20to%202021.pdf

Microsoft word - january 05 osteoporosis

VOLUME 5, ISSUE 1 In Good Hands A Free Monthly Newsletter For The Friends and Patients of: Dr. C.J. Valenti “The AmazingWeight Loss Secret Of The South African Bushman Finally Stumbled Upon After Thousands of Years…” estlake- Ever wanted to just take a pill and shed a “Eat that – and you will never be W fewofthoseextrapoundsyou’vegothangin’ hungry or thirsty a

Itaoggi045 (df).indd

M rcoledì 25 Settembre 2013 45 DOTTORI COMMERCIALISTI ED ESPERTI CONTABILI DI ROMA L’Odcec di Roma ha previsto l’organizzazione di 250 eventi formativi nel 2013 Più formazione per crescere Nel futuro della Fpc sempre più on-line e specializzazione Iscrizione agli esami di Stato I tirocinanti che intendono sostenere l’esame di Stato rappresenta una

Copyright © 2010-2014 Medical Articles